What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.

Animals B7-H1 Antigen / genetics Cell Line, Tumor CpG Islands / genetics DNA Methylation / genetics Epigenesis, Genetic Gene Expression Gene Expression Regulation, Neoplastic Histone Code / genetics Histones / genetics Humans Male MicroRNAs / genetics Promoter Regions, Genetic / genetics Prostatic Neoplasms / genetics
DNA methylation PD-L1 cancer checkpoint inhibitors epigenetic immunotherapy miRNA prostate

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Nov 2021
Historique:
received: 12 08 2021
revised: 18 10 2021
accepted: 22 10 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 21 12 2021
Statut: epublish

Résumé

Epigenetic alterations (including DNA methylation or miRNAs) influence oncogene/oncosuppressor gene expression without changing the DNA sequence. Prostate cancer (PC) displays a complex genetic and epigenetic regulation of cell-growth pathways and tumor progression. We performed a systematic literature review (following PRISMA guidelines) focused on the epigenetic regulation of PD-L1 expression in PC. In PC cell lines, CpG island methylation of the

Identifiants

DOI: 10.3390/ijms222212314 PMID: 34830196 PMC: PMC8619683
pubmed: 34830196
pii: ijms222212314
doi: 10.3390/ijms222212314
pmc: PMC8619683
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
Histones 0
MicroRNAs 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Références

Sci Rep. 2013 Nov 06;3:3151
pubmed: 24193225
PLoS One. 2011 May 04;6(5):e19337
pubmed: 21573239
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
J Immunother. 2019 Sep;42(7):269-273
pubmed: 31261165
Oncoimmunology. 2020 Feb 11;9(1):1721810
pubmed: 32117585
Urol Oncol. 2021 May;39(5):298.e13-298.e20
pubmed: 33712343
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616555
BMC Cancer. 2015 Mar 31;15:204
pubmed: 25884570
Commun Biol. 2021 Jan 26;4(1):119
pubmed: 33500545
PLoS One. 2016 Nov 15;11(11):e0166626
pubmed: 27846317
Oncotarget. 2017 Apr 18;8(16):26789-26801
pubmed: 28460462
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
PLoS One. 2019 Nov 22;14(11):e0224071
pubmed: 31756185
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32269146
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27599530
Microorganisms. 2021 Jan 03;9(1):
pubmed: 33401648
APMIS. 2018 Mar;126(3):267-272
pubmed: 29411910
Cancers (Basel). 2021 Sep 08;13(18):
pubmed: 34572754
Mol Cell. 2019 Jan 3;73(1):22-35.e6
pubmed: 30527665
Small. 2019 Dec;15(52):e1904378
pubmed: 31697036
Lancet. 2005 Jul 9-15;366(9480):107-8
pubmed: 16005318
Oncoimmunology. 2020 Apr 14;9(1):1744980
pubmed: 32363112
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Oncogene. 2019 Jul;38(28):5700-5724
pubmed: 31043708
Cell Immunol. 2014 Jul;290(1):72-9
pubmed: 24908630
J Immunother Cancer. 2019 Aug 14;7(1):218
pubmed: 31412954
J Cancer. 2020 Jan 1;11(3):648-656
pubmed: 31942188
Theranostics. 2020 Jan 1;10(3):1033-1045
pubmed: 31938049
Nucleic Acids Res. 2016 Feb 18;44(3):1105-17
pubmed: 26464434
PLoS One. 2013 Dec 31;8(12):e83991
pubmed: 24391862
Clin Cancer Res. 2021 Jun 15;27(12):3360-3369
pubmed: 33568344
J Immunother Cancer. 2018 Sep 18;6(1):91
pubmed: 30227893
Oncoimmunology. 2014 Dec 13;3(9):e955331
pubmed: 25941611
Cancer Cell Int. 2020 Aug 15;20:394
pubmed: 32821247
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92
pubmed: 22474386
Ther Adv Med Oncol. 2020 Aug 25;12:1758835920936084
pubmed: 32922519
Cancer Immunol Immunother. 2021 Mar;70(3):701-712
pubmed: 32909077
Prostate. 2021 Jan;81(1):50-57
pubmed: 32986884
J Immunother Cancer. 2019 Nov 8;7(1):293
pubmed: 31703602
Prostate. 2019 Apr;79(5):498-505
pubmed: 30614027
J Drug Target. 2020 Jun;28(5):508-515
pubmed: 31865764
Diagnostics (Basel). 2021 Jan 29;11(2):
pubmed: 33572888
Cancers (Basel). 2021 Jul 01;13(13):
pubmed: 34282774
Oncologist. 2016 Dec;21(12):1427-1435
pubmed: 27628492
Pathol Res Pract. 2016 May;212(5):475-83
pubmed: 26876782
Acta Biochim Biophys Sin (Shanghai). 2010 Jun 15;42(6):363-9
pubmed: 20539944
J Immunother Cancer. 2018 Nov 29;6(1):133
pubmed: 30486888
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Hum Pathol. 2018 Dec;82:131-139
pubmed: 30075156
Int J Surg Pathol. 2022 Apr;30(2):177-183
pubmed: 34180727
J Pathol. 2008 Jul;215(3):211-3
pubmed: 18523970
Cancer Res. 2014 Mar 15;74(6):1870-1880
pubmed: 24480624
Nature. 2002 Apr 4;416(6880):552-6
pubmed: 11932749
Cytopathology. 2020 May;31(3):185-192
pubmed: 31749241
J Transl Med. 2020 May 28;18(1):214
pubmed: 32466781
Clin Cancer Res. 2015 Nov 1;21(21):4922-34
pubmed: 26080838
Med Oncol. 2020 Jul 21;37(8):66
pubmed: 32696094
Cell Physiol Biochem. 2018;48(2):801-814
pubmed: 30032144
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819886867
pubmed: 31694481
Am J Clin Exp Urol. 2019 Jun 15;7(3):159-169
pubmed: 31317055
Int J Mol Sci. 2019 Apr 13;20(8):
pubmed: 31013891
Cancer Lett. 2017 Oct 10;406:27-35
pubmed: 28797844
Cells. 2021 Nov 14;10(11):
pubmed: 34831388
Diagnostics (Basel). 2021 Feb 04;11(2):
pubmed: 33557386
Immunotargets Ther. 2020 Jul 27;9:115-130
pubmed: 32802803
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Clin Genitourin Cancer. 2017 Oct;15(5):577-581
pubmed: 28461179
BMC Cancer. 2018 Nov 15;18(1):1115
pubmed: 30442097
Nat Med. 2017 Sep;23(9):1063-1071
pubmed: 28805820
Theranostics. 2021 Mar 4;11(10):4809-4824
pubmed: 33754029
Medicine (Baltimore). 2020 May;99(19):e20124
pubmed: 32384491
Nucleic Acids Res. 2007;35(1):100-12
pubmed: 17151075
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):184-193
pubmed: 31611635
Medicina (Kaunas). 2016;52(2):116-24
pubmed: 27170485
Ital J Gastroenterol Hepatol. 1997 Dec;29(6):558-63
pubmed: 9513833
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Front Cell Dev Biol. 2021 Jun 14;9:646884
pubmed: 34195187
Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):454-463
pubmed: 30385408
Pathol Res Pract. 2019 Apr;215(4):828-831
pubmed: 30683477
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Mol Ther Oncolytics. 2016 Dec 14;4:41-54
pubmed: 28345023
Bioconjug Chem. 2018 Jan 17;29(1):96-103
pubmed: 29125731
Anal Chem. 2018 Mar 20;90(6):3744-3751
pubmed: 29464943
Am J Pathol. 2018 Jun;188(6):1478-1485
pubmed: 29577933
Oncotarget. 2015 Jan 1;6(1):234-42
pubmed: 25428917
Oncoimmunology. 2018 Feb 14;7(6):e1431088
pubmed: 29872559
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33692219
Clin Cancer Res. 2020 Jul 1;26(13):3182-3192
pubmed: 32173650
Eur Urol Focus. 2019 Mar;5(2):192-196
pubmed: 28753812
Mol Cancer Res. 2018 Feb;16(2):243-255
pubmed: 29117944
Clin Cancer Res. 2018 Dec 1;24(23):5948-5962
pubmed: 30337279
J Immunother Cancer. 2018 Dec 4;6(1):141
pubmed: 30514390
Int J Mol Sci. 2021 Nov 15;22(22):
pubmed: 34830209
Prostate. 2021 Feb;81(3):147-156
pubmed: 33368414
BMC Surg. 2019 May 28;19(1):55
pubmed: 31138190
Cancer Cell. 2020 Oct 12;38(4):489-499.e3
pubmed: 32916128
Nature. 2015 May 7;521(7550):94-8
pubmed: 25924065
Ann Oncol. 2018 Aug 1;29(8):1807-1813
pubmed: 29992241
J Clin Pathol. 2018 Nov;71(11):1023-1027
pubmed: 30257853
PLoS One. 2018 Nov 6;13(11):e0206818
pubmed: 30399174
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
J Immunother. 2012 Feb-Mar;35(2):169-78
pubmed: 22306905
Oncotarget. 2016 Nov 29;7(48):79943-79955
pubmed: 27835597
Indian J Pathol Microbiol. 2019 Jul-Sep;62(3):405-412
pubmed: 31361228
Int J Biol Markers. 2018 Nov;33(4):540-544
pubmed: 30101629
Cancer Lett. 2018 Sep 1;431:1-10
pubmed: 29751044
Front Oncol. 2014 May 01;4:80
pubmed: 24822169
BMC Pulm Med. 2019 Nov 19;19(1):216
pubmed: 31744552
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Cell Biol Int. 2019 Jun;43(6):642-650
pubmed: 30958600
Carcinogenesis. 2010 Jan;31(1):27-36
pubmed: 19752007
Prostate. 2018 Apr;78(5):353-364
pubmed: 29330929
J Cancer. 2019 Jun 2;10(14):3102-3111
pubmed: 31289580
Pathol Res Pract. 2016 Oct;212(10):946-953
pubmed: 27499153
Clin Genitourin Cancer. 2019 Apr;17(2):145-153.e5
pubmed: 30709785
Mol Cell. 2018 Feb 1;69(3):533
pubmed: 29395069
Oncotarget. 2015 Dec 22;6(41):43267-80
pubmed: 26657115
Cancers (Basel). 2021 Sep 12;13(18):
pubmed: 34572803
Cell Physiol Biochem. 2017;42(6):2453-2466
pubmed: 28848163
Diagnostics (Basel). 2021 Jan 07;11(1):
pubmed: 33430341
Prostate Int. 2013;1(1):3-9
pubmed: 24223395
Clin Cancer Res. 2017 Nov 15;23(22):6812-6822
pubmed: 28893901
Urol Oncol. 2019 May;37(5):297.e19-297.e31
pubmed: 30827759
APMIS. 2019 Aug;127(8):554-560
pubmed: 31127651
Sci Rep. 2016 Feb 29;6:22051
pubmed: 26924343
Clin Cancer Res. 2019 Jun 1;25(11):3220-3228
pubmed: 30770348
Ther Adv Urol. 2015 Dec;7(6):388-95
pubmed: 26622323
Fetal Pediatr Pathol. 2014 Apr;33(2):71-83
pubmed: 23883335
Mol Cell. 2005 Aug 19;19(4):523-34
pubmed: 16109376
Medicine (Baltimore). 2019 Sep;98(38):e17257
pubmed: 31567999
Prostate. 2012 Aug 1;72(11):1193-9
pubmed: 22161972
Clin Cancer Res. 2016 Apr 15;22(8):1969-77
pubmed: 26573597
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):73-81
pubmed: 25442346
Mol Med Rep. 2018 May;17(5):7045-7054
pubmed: 29568923
Biomed Pharmacother. 2018 Aug;104:637-644
pubmed: 29803177
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Int J Biol Sci. 2019 Mar 9;15(5):919-928
pubmed: 31182913
Mol Ther. 2020 Nov 4;28(11):2473-2487
pubmed: 32592689
Am J Clin Exp Urol. 2016 Jan 28;4(1):1-8
pubmed: 27069956
Cancer Res. 2017 Apr 15;77(8):2040-2051
pubmed: 28235763
Sci Rep. 2016 Jul 01;6:28910
pubmed: 27363678
Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625
pubmed: 29679564
Biomark Res. 2021 Feb 18;9(1):14
pubmed: 33602330
Curr Top Dev Biol. 2004;60:55-89
pubmed: 15094296
Oncotarget. 2015 Dec 22;6(41):43819-30
pubmed: 26540468
Oncology. 2021;99(6):345-358
pubmed: 33735905
Mol Imaging Biol. 2020 Dec;22(6):1553-1561
pubmed: 32813112
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Neuropathology. 2017 Dec;37(6):517-525
pubmed: 28548244
FEBS Open Bio. 2019 Jun;9(6):1063-1070
pubmed: 31090214
Cell Death Dis. 2018 Feb 5;9(2):155
pubmed: 29449534
J Clin Med. 2020 Aug 06;9(8):
pubmed: 32781666
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499258
Br J Cancer. 2020 Sep;123(7):1089-1100
pubmed: 32641865
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
J Clin Invest. 2016 Dec 1;126(12):4585-4602
pubmed: 27820701
Cancer Microenviron. 2018 Jun;11(1):41-49
pubmed: 29357011
Cell Death Dis. 2019 Aug 20;10(9):631
pubmed: 31431617
Mol Oncol. 2018 Mar;12(3):269-286
pubmed: 28865178
Eur Urol Focus. 2018 Jan;4(1):75-79
pubmed: 28753790
BMC Med Genomics. 2017 Dec 06;10(1):74
pubmed: 29212506
Diagnostics (Basel). 2021 Apr 14;11(4):
pubmed: 33919741
Urologe A. 2017 Nov;56(11):1471-1472
pubmed: 28980011
Nature. 2017 Oct 5;550(7674):128-132
pubmed: 28953875
Prostate. 2019 Feb;79(3):320-330
pubmed: 30488530
Cancer Immunol Res. 2020 Jul;8(7):844-850
pubmed: 32321776
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668490
J BUON. 2018 Nov-Dec;23(6):1796-1802
pubmed: 30610805
Diagnostics (Basel). 2021 Aug 25;11(9):
pubmed: 34573885
Int J Mol Sci. 2021 Nov 14;22(22):
pubmed: 34830179
Cell Death Differ. 2010 Feb;17(2):215-20
pubmed: 19498445
J Cell Physiol. 2019 May;234(5):5496-5506
pubmed: 30246332
BMC Cancer. 2021 Apr 27;21(1):468
pubmed: 33906629
Immunity. 2013 Nov 14;39(5):819-32
pubmed: 24238339
Oncogene. 2020 May;39(19):3939-3951
pubmed: 32203167
J Immunother Cancer. 2019 Oct 25;7(1):277
pubmed: 31653272
Oncoimmunology. 2014 Dec 21;3(11):e963413
pubmed: 25914862
Nat Med. 2020 Jan;26(1):39-46
pubmed: 31873309
Urologiia. 2019 Sep;(4):51-57
pubmed: 31535805
Clin Cancer Res. 2021 Jun 1;27(11):3253-3264
pubmed: 33753455
BMC Cancer. 2021 Apr 13;21(1):399
pubmed: 33849473
Clin Cancer Res. 2015 Oct 1;21(19):4278-85
pubmed: 26199389
Biochem J. 2020 Nov 27;477(22):4367-4381
pubmed: 33094805
Theranostics. 2017 Aug 22;7(14):3585-3594
pubmed: 28912897
Nat Med. 2008 Nov;14(11):1271-7
pubmed: 18931683
Biomed Pharmacother. 2021 May;137:111339
pubmed: 33550044
APMIS. 2017 Sep;125(9):844-848
pubmed: 28543860
Oncotarget. 2016 Aug 16;7(33):53309-53320
pubmed: 27462860
Stem Cells. 2009 Aug;27(8):1712-21
pubmed: 19544444
Cancer Gene Ther. 2019 Nov;26(11-12):388-399
pubmed: 30607005
Contemp Oncol (Pozn). 2015;19(6):423-7
pubmed: 26843836
Clin Epigenetics. 2021 Jun 8;13(1):125
pubmed: 34103085
J Clin Invest. 2018 Oct 1;128(10):4441-4453
pubmed: 30179225
Clin Cancer Res. 2020 Sep 15;26(18):5019-5035
pubmed: 32605911
APMIS. 2020 Mar;128(3):191-200
pubmed: 31697865
Int J Gynecol Pathol. 2021 Sep 1;40(5):441-447
pubmed: 33252401
Sci Adv. 2020 Sep 18;6(38):
pubmed: 32948597
Oncotarget. 2016 Apr 12;7(15):20840-54
pubmed: 26956044
Target Oncol. 2016 Jun;11(3):345-51
pubmed: 26566945
Mol Med Rep. 2019 Nov;20(5):4244-4252
pubmed: 31545446
Nat Cancer. 2021 Apr;2(4):444-456
pubmed: 33899001
Oncotarget. 2016 Mar 1;7(9):10557-67
pubmed: 26859684
Cancer Biother Radiopharm. 2014 May;29(4):153-61
pubmed: 24693958
APMIS. 2018 Sep;126(9):771-776
pubmed: 30160016
Exp Cell Res. 2018 Mar 1;364(1):113-123
pubmed: 29408565
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Cancers (Basel). 2021 Jun 03;13(11):
pubmed: 34205136
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32
pubmed: 26260996
Oncotarget. 2017 Dec 04;9(12):10284-10293
pubmed: 29535806
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
J Clin Invest. 2018 Aug 31;128(9):3813-3818
pubmed: 29905573
Cancers (Basel). 2021 Feb 17;13(4):
pubmed: 33671249
Mol Oncol. 2021 May;15(5):1358-1375
pubmed: 33338321
Zhonghua Nan Ke Xue. 2016 Nov;22(11):963-967
pubmed: 29281201
Oncotarget. 2016 Jun 21;7(25):37993-38003
pubmed: 27191272
Int J Biol Sci. 2020 Feb 21;16(8):1417-1426
pubmed: 32210729
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):22-36
pubmed: 29282359
Medicine (Baltimore). 2021 Jun 04;100(22):e25863
pubmed: 34087828
Oncotarget. 2017 Jul 18;8(29):47474-47489
pubmed: 28537896
Oncotarget. 2017 Jun 21;8(32):53518-53530
pubmed: 28881828
Oncotarget. 2017 Aug 18;8(42):72755-72772
pubmed: 29069824
Nat Genet. 2006 Dec;38(12):1378-85
pubmed: 17072317
Aging Cell. 2019 Dec;18(6):e13027
pubmed: 31493351
Cancer Immunol Res. 2014 Mar;2(3):187-93
pubmed: 24778314
Cells. 2021 Nov 14;10(11):
pubmed: 34831389
Oncotarget. 2018 May 22;9(39):25586-25596
pubmed: 29876010
J Thorac Oncol. 2017 Sep;12(9):1421-1433
pubmed: 28629895
Oncoimmunology. 2016 Mar 28;5(6):e1165377
pubmed: 27471641
Nat Commun. 2021 Mar 3;12(1):1426
pubmed: 33658518
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671573
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Mol Med Rep. 2018 Jun;17(6):8111-8120
pubmed: 29693186
Cancer Immunol Res. 2015 Aug;3(8):946-55
pubmed: 26041735
Int J Cancer. 2019 Jun 15;144(12):3099-3110
pubmed: 30537104
Sci Rep. 2019 Jul 23;9(1):10662
pubmed: 31337863
G Ital Cardiol (Rome). 2013 Jun;14(6):481-4
pubmed: 23748548

Auteurs

Andrea Palicelli (A)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0003-2299-5160

Stefania Croci (S)

Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0002-8622-0439

Alessandra Bisagni (A)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0001-8484-7871

Eleonora Zanetti (E)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0002-3483-130X

Dario De Biase (D)

Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy.
ORCID: 0000-0002-0609-8817

Beatrice Melli (B)

Fertility Center, Department of Obstetrics and Gynecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy.
ORCID: 0000-0003-1366-2081

Francesca Sanguedolce (F)

Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.

Moira Ragazzi (M)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Magda Zanelli (M)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0002-8733-9933

Alcides Chaux (A)

Department of Scientific Research, School of Postgraduate Studies, Norte University, Asunción 1614, Paraguay.

Sofia Cañete-Portillo (S)

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Maria Paola Bonasoni (MP)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Alessandra Soriano (A)

Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Gastroenterology Division, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Stefano Ascani (S)

Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.
Haematopathology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy.

Maurizio Zizzo (M)

Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0001-9841-7856

Carolina Castro Ruiz (C)

Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Antonio De Leo (A)

Molecular Diagnostic Unit, Azienda USL Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.
ORCID: 0000-0002-3761-5135

Guido Giordano (G)

Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.

Matteo Landriscina (M)

Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
ORCID: 0000-0003-0591-9799

Giuseppe Carrieri (G)

Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy.

Luigi Cormio (L)

Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy.

Daniel M Berney (DM)

Barts Cancer Institute, Queen Mary University of London, London EC1M 5PZ, UK.

Jatin Gandhi (J)

Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.

Davide Nicoli (D)

Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0002-1662-0103

Enrico Farnetti (E)

Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Giacomo Santandrea (G)

Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy.
ORCID: 0000-0001-5487-0683

Martina Bonacini (M)

Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
ORCID: 0000-0002-6830-6781

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Ilots CpG › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Méthylation de l'ADN › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Code histone › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Histone › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Composants de gène › Éléments de régulation transcriptionnelle › Régions promotrices (génétique) › What Do We Have to Know about PD-L1 Expression...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › What Do We Have to Know about PD-L1 Expression...